Logo image of NRXP

NRX PHARMACEUTICALS INC (NRXP) Stock Fundamental Analysis

NASDAQ:NRXP - Nasdaq - US6294442099 - Common Stock - Currency: USD

2.05  -0.07 (-3.3%)

Fundamental Rating

0

Overall NRXP gets a fundamental rating of 0 out of 10. We evaluated NRXP against 198 industry peers in the Pharmaceuticals industry. NRXP may be in some trouble as it scores bad on both profitability and health. NRXP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRXP has reported negative net income.
NRXP had a negative operating cash flow in the past year.
NRXP had negative earnings in each of the past 5 years.
NRXP had a negative operating cash flow in each of the past 5 years.
NRXP Yearly Net Income VS EBIT VS OCF VS FCFNRXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -688.20%, NRXP is doing worse than 94.95% of the companies in the same industry.
Industry RankSector Rank
ROA -688.2%
ROE N/A
ROIC N/A
ROA(3y)-418.16%
ROA(5y)-467.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXP Yearly ROA, ROE, ROICNRXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

NRXP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRXP Yearly Profit, Operating, Gross MarginsNRXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, NRXP has less shares outstanding
The number of shares outstanding for NRXP has been increased compared to 5 years ago.
The debt/assets ratio for NRXP is higher compared to a year ago.
NRXP Yearly Shares OutstandingNRXP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NRXP Yearly Total Debt VS Total AssetsNRXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -129.82, we must say that NRXP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -129.82, NRXP is doing worse than 94.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -129.82
ROIC/WACCN/A
WACCN/A
NRXP Yearly LT Debt VS Equity VS FCFNRXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

NRXP has a Current Ratio of 0.15. This is a bad value and indicates that NRXP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.15, NRXP is not doing good in the industry: 95.45% of the companies in the same industry are doing better.
NRXP has a Quick Ratio of 0.15. This is a bad value and indicates that NRXP is not financially healthy enough and could expect problems in meeting its short term obligations.
NRXP has a worse Quick ratio (0.15) than 94.95% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
NRXP Yearly Current Assets VS Current LiabilitesNRXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

NRXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.25%, which is quite impressive.
EPS 1Y (TTM)42.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NRXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y100%
EPS Next 2Y52.9%
EPS Next 3Y47.41%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRXP Yearly Revenue VS EstimatesNRXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
NRXP Yearly EPS VS EstimatesNRXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2026 2027 0 2 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NRXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRXP Price Earnings VS Forward Price EarningsNRXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXP Per share dataNRXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

NRXP's earnings are expected to grow with 47.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.9%
EPS Next 3Y47.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NRX PHARMACEUTICALS INC

NASDAQ:NRXP (5/1/2025, 12:44:18 PM)

2.05

-0.07 (-3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-14 2025-03-14/amc
Earnings (Next)05-12 2025-05-12
Inst Owners5.94%
Inst Owner Change0%
Ins Owners15.78%
Ins Owner Change4.6%
Market Cap34.69M
Analysts82.22
Price Target28.82 (1305.85%)
Short Float %8.87%
Short Ratio6.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.15%
Min EPS beat(2)-138.39%
Max EPS beat(2)80.09%
EPS beat(4)2
Avg EPS beat(4)-21.18%
Min EPS beat(4)-138.39%
Max EPS beat(4)80.09%
EPS beat(8)5
Avg EPS beat(8)-1.68%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.79%
PT rev (3m)-10.79%
EPS NQ rev (1m)6.25%
EPS NQ rev (3m)50%
EPS NY rev (1m)100%
EPS NY rev (3m)100%
Revenue NQ rev (1m)-50.02%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-50.2%
Revenue NY rev (3m)-50.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.31
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS-1.37
TBVpS-1.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -688.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-418.16%
ROA(5y)-467.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -129.82
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54%
EPS Next Y100%
EPS Next 2Y52.9%
EPS Next 3Y47.41%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.88%
OCF growth 3YN/A
OCF growth 5YN/A